Today: 27 June 2026
Browse Category

BSE:517174 19 December 2025

Honeywell Automation India Share Price Today (19 Dec 2025): HONAUT Stock News, Q2 FY26 Results, Bulk Deal, Valuation and Analyst Targets

Honeywell Automation India Share Price Today (19 Dec 2025): HONAUT Stock News, Q2 FY26 Results, Bulk Deal, Valuation and Analyst Targets

Honeywell Automation India traded near ₹33,900 midday Friday, up about 0.8%. The stock is down roughly 10% over six months and 15% over the past year, despite reporting Q2 FY26 revenue of ₹11,494 million and net profit of ₹1,195 million. Its 52-week range is ₹31,025 to ₹43,732.55.

Stock Market Today

  • Dollar Drops on Lower Crude Prices, Easing Fed Rate-Hike Fears
    June 27, 2026, 10:22 AM EDT. The U.S. dollar slipped 0.07% on Friday as WTI crude oil prices fell over 3% to a four-month low, reducing inflation concerns and lessening expectations of aggressive Federal Reserve interest rate hikes. The University of Michigan's June consumer sentiment index came in weaker than expected, pressuring the dollar further. However, hawkish comments from Minneapolis Fed President Neel Kashkari, expressing inflation concerns and support for a rate increase, helped the dollar partially recover. Euro gained 0.12%, bolstered by the weaker dollar and Europe's energy import reliance benefiting from lower oil prices. The yen strengthened modestly against the dollar following higher-than-expected Tokyo CPI inflation and a 4% Nikkei drop, boosting safe-haven demand despite concerns over Bank of Japan's slow policy normalization.

Latest articles

Moderna (NASDAQ:MRNA) price targets draw attention as shares rally into short holiday week

Moderna (NASDAQ:MRNA) price targets draw attention as shares rally into short holiday week

27 June 2026
Moderna soared 12.6% Friday on heavy volume after unveiling new in vivo CAR-T pipeline plans, closing at $67.27—52% above the mean analyst target but still 14.5% below Piper Sandler’s new $77 target. The rally followed Science Day updates, even as analysts note the main new asset is preclinical and cash burn continues, with $7.5B cash at March-end and a projected $3B R&D spend for 2026.
Go toTop